Screener
Capricor Therapeutics CAPR EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Capricor Therapeutics’s 10-Q, filed August 14, 2026. Open the filing →
- Filed
- Aug 14, 2026, 4:46 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-097294
FAQ
- What is Capricor Therapeutics's EPS (diluted)?
- Capricor Therapeutics (CAPR) reported EPS (diluted) of -$0.70 in Q2 2026.
- How has Capricor Therapeutics's EPS (diluted) changed year-over-year?
- Capricor Therapeutics's EPS (diluted) decreased by 22.8% year-over-year, from -$0.57 to -$0.70.
- What is the long-term trend for Capricor Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Capricor Therapeutics's EPS (diluted) has grown at a 27.0% compound annual growth rate (CAGR), from -$0.87 to -$2.26.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Capricor Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude